Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 19040996)

1.

Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.

Ruan DT, Warren RS, Moalem J, Chung KW, Griffin AC, Shen W, Duh QY, Nakakura E, Donner DB, Khanafshar E, Weng J, Clark OH, Kebebew E.

Surgery. 2008 Dec;144(6):908-13; discussion 913-4. doi: 10.1016/j.surg.2008.07.028.

PMID:
19040996
2.

BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.

Zerilli M, Zito G, Martorana A, Pitrone M, Cabibi D, Cappello F, Giordano C, Rodolico V.

Mod Pathol. 2010 Aug;23(8):1052-60. doi: 10.1038/modpathol.2010.86. Epub 2010 May 14.

3.

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.

Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK.

Clin Endocrinol (Oxf). 2006 Sep;65(3):364-8.

PMID:
16918957
4.

BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma.

Ahn D, Park JS, Sohn JH, Kim JH, Park SK, Seo AN, Park JY.

Auris Nasus Larynx. 2012 Apr;39(2):198-203. doi: 10.1016/j.anl.2011.07.011. Epub 2011 Aug 20.

PMID:
21862261
5.

Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation.

Musholt TJ, Schönefeld S, Schwarz CH, Watzka FM, Musholt PB, Fottner C, Weber MM, Springer E, Schad A.

Langenbecks Arch Surg. 2010 Sep;395(7):877-83. doi: 10.1007/s00423-010-0682-6. Epub 2010 Jul 18.

PMID:
20640859
6.

Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?

Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, Park WC, Kim JS, Jung SS, Bae JS.

Am J Surg. 2012 Apr;203(4):436-41. doi: 10.1016/j.amjsurg.2011.02.013. Epub 2011 Jul 30.

PMID:
21803329
7.

Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.

Koperek O, Kornauth C, Capper D, Berghoff AS, Asari R, Niederle B, von Deimling A, Birner P, Preusser M.

Am J Surg Pathol. 2012 Jun;36(6):844-50. doi: 10.1097/PAS.0b013e318246b527. Erratum in: Am J Surg Pathol. 2012 Oct;36(10):1578.

PMID:
22592144
8.

The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.

Riesco-Eizaguirre G, Gutiérrez-Martínez P, García-Cabezas MA, Nistal M, Santisteban P.

Endocr Relat Cancer. 2006 Mar;13(1):257-69.

9.

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

Howell GM, Carty SE, Armstrong MJ, Lebeau SO, Hodak SP, Coyne C, Stang MT, McCoy KL, Nikiforova MN, Nikiforov YE, Yip L.

Ann Surg Oncol. 2011 Dec;18(13):3566-71. doi: 10.1245/s10434-011-1781-5. Epub 2011 May 19.

PMID:
21594703
10.

Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.

Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB, Nikiforov YE.

Surgery. 2009 Dec;146(6):1215-23. doi: 10.1016/j.surg.2009.09.011.

PMID:
19958951
11.

BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability.

Barollo S, Pennelli G, Vianello F, Watutantrige Fernando S, Negro I, Merante Boschin I, Pelizzo MR, Rugge M, Mantero F, Nacamulli D, Girelli ME, Busnardo B, Mian C.

Eur J Endocrinol. 2010 Oct;163(4):659-63. doi: 10.1530/EJE-10-0290. Epub 2010 Jul 20.

12.

BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis.

Gauchotte G, Philippe C, Lacomme S, Léotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM, Bressenot A.

Pathology. 2011 Aug;43(5):447-52. doi: 10.1097/PAT.0b013e3283486178.

PMID:
21716161
13.

BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.

O'Neill CJ, Bullock M, Chou A, Sidhu SB, Delbridge LW, Robinson BG, Gill AJ, Learoyd DL, Clifton-Bligh R, Sywak MS.

Surgery. 2010 Dec;148(6):1139-45; discussion 1145-6. doi: 10.1016/j.surg.2010.09.005.

PMID:
21134544
14.

Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.

Wang Y, Ji M, Wang W, Miao Z, Hou P, Chen X, Xu F, Zhu G, Sun X, Li Y, Condouris S, Liu D, Yan S, Pan J, Xing M.

Endocr Relat Cancer. 2008 Mar;15(1):183-90. doi: 10.1677/ERC-07-0182.

15.

BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.

Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.

Cancer. 2007 Sep 15;110(6):1218-26.

16.

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. Epub 2007 Dec 5.

PMID:
18070147
17.

BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.

Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo do H, Youn YK.

World J Surg. 2012 Feb;36(2):310-7. doi: 10.1007/s00268-011-1383-1.

PMID:
22190222
18.

BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.

Gu LQ, Li FY, Zhao L, Liu Y, Zang XX, Wang TX, Chen HP, Ning G, Zhao YJ.

Thyroid. 2009 Apr;19(4):347-54. doi: 10.1089/thy.2008.0246.

PMID:
19355825
19.

Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis.

Kim KH, Suh KS, Kang DW, Kang DY.

Pathol Int. 2005 Sep;55(9):540-5.

PMID:
16143028
20.

BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies.

Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, Rossi R, Cavazzini L, Roti E, degli Uberti EC.

Eur J Endocrinol. 2009 Sep;161(3):467-73. doi: 10.1530/EJE-09-0353. Epub 2009 Jul 2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk